Notice of Meeting, 33373-33374 [2024-09047]

Download as PDF Federal Register / Vol. 89, No. 83 / Monday, April 29, 2024 / Notices Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Vera A. Cherkasova, Ph.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Health, 6710B Rockledge Drive, Room 2137B, Bethesda, MD 20892, (240) 478–4580, vera.cherkasova@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: April 24, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–09108 Filed 4–26–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSKJM1Z7X2PROD with NOTICES Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Child Health and Human Development Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will also be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which VerDate Sep<11>2014 20:54 Apr 26, 2024 Jkt 262001 would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Child Health and Human Development Council. Date: June 3–4, 2024. Open: June 3, 2024, 10:00 a.m. to 5:00 p.m. Agenda: Opening Remarks, Administrative Matters, NICHD Director’s Report, and other business of the Council. Place: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 1425 & 142, Bethesda, MD 20817 (Hybrid). Closed: June 4, 2024, 9:30 a.m. to 12:30 p.m. Agenda: To review and evaluate grant applications. Place: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 1425 & 1427, Bethesda, MD 20817 (Hybrid). Contact Person: Rebekah S. Rasooly, Ph.D., Director, Division of Extramural Activities, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Room 2316, Bethesda, MD 20817. Information is also available on the Institute’s/Center’s home page: https:// www.nichd.nih.gov/about/advisory/council, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: April 23, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–09055 Filed 4–26–24; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial Frm 00062 Fmt 4703 property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Eunice Kennedy Shriver National Institute of Child Health and Human Development Special Emphasis Panel; Developmental Biology/Member Conflict. Date: June 7, 2024 Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Vera A. Cherkasova, Ph.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Health, 6710B Rockledge Drive, Room 2137B, Bethesda, MD 20892, (240) 478–4580, vera.cherkasova@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: April 24, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–09113 Filed 4–26–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Notice of Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 33373 Sfmt 4703 Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene in open session in person and via web conference on June 4th, 2024, from 10:00 a.m. EST to 5:00 p.m. EST and in closed session on June 5th, 2024 from 9:00 a.m. EST to 12:00 p.m. EST. The board will meet in open-session June 4, 2024, from 10:00 a.m. EST to 5:00 p.m. EST to discuss the Mandatory Guidelines for Federal Workplace Drug Testing Programs, hear updates from the Nuclear Regulatory Commission, and discuss the availability of FDA 510(k) cleared assays and urine verses oral fluid prevalence data and specimen E:\FR\FM\29APN1.SGM 29APN1 khammond on DSKJM1Z7X2PROD with NOTICES 33374 Federal Register / Vol. 89, No. 83 / Monday, April 29, 2024 / Notices validity and biomarker testing. Presentations include one by Faye Caldwell on industry moving parts pertaining to Oral Fluid implementation and another by Dr. Edward Cone regarding Johns Hopkins University study updates. The board will meet in closed session on June 5, 2024, from 9:00 a.m. EST to 12:00 p.m. EST to discuss specimen validity testing data, challenges to Oral Fluid testing and the status of the Hair Mandatory Guidelines. All of these topics require input and discussion from Board Members as to the next steps of Federal Workplace Drug Testing. The DTAB meeting on June 5, 2024, from 9:00 a.m. EST to 12:00 p.m. EST, is closed to the public, as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d). Meeting registration information can be completed at https://snacregister. samhsa.gov/. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, https://www.samhsa.gov/ about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis. Committee Name: Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Drug Testing Advisory Board. Dates/Time/Type: June 4, 2024, from 10:00 a.m. EST to 5:00 p.m. EST: OPEN; June 5, 2024, from 9:00 a.m. EST to 12:00 p.m. EST: CLOSED. Place: Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857. To Submit Comments: Please send comments in writing at least 7 days prior to the meeting to the to the following email: DFWP@ samhsa.hhs.gov. Contact: Lisa S. Davis, M.S, Social Science Analyst, Center for Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (240) 276–1440, Email: Lisa.Davis@ samhsa.hhs.gov. Anastasia Flanagan, Public Health Advisor, Division of Workplace Programs. [FR Doc. 2024–09047 Filed 4–26–24; 8:45 am] BILLING CODE 4162–20–P VerDate Sep<11>2014 20:54 Apr 26, 2024 Jkt 262001 DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID FEMA–2024–0002; Internal Agency Docket No. FEMA–B–2430] Proposed Flood Hazard Determinations Federal Emergency Management Agency, Department of Homeland Security. ACTION: Notice. Comments are requested on proposed flood hazard determinations, which may include additions or modifications of any Base Flood Elevation (BFE), base flood depth, Special Flood Hazard Area (SFHA) boundary or zone designation, or regulatory floodway on the Flood Insurance Rate Maps (FIRMs), and where applicable, in the supporting Flood Insurance Study (FIS) reports for the communities listed in the table below. The purpose of this notice is to seek general information and comment regarding the preliminary FIRM, and where applicable, the FIS report that the Federal Emergency Management Agency (FEMA) has provided to the affected communities. The FIRM and FIS report are the basis of the floodplain management measures that the community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the National Flood Insurance Program (NFIP). DATES: Comments are to be submitted on or before July 29, 2024. ADDRESSES: The Preliminary FIRM, and where applicable, the FIS report for each community are available for inspection at both the online location https://hazards.fema.gov/femaportal/ prelimdownload and the respective Community Map Repository address listed in the tables below. Additionally, the current effective FIRM and FIS report for each community are accessible online through the FEMA Map Service Center at https:// msc.fema.gov for comparison. You may submit comments, identified by Docket No. FEMA–B–2430, to Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646–7659, or (email) patrick.sacbibit@fema.dhs.gov. FOR FURTHER INFORMATION CONTACT: Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 FEMA proposes to make flood hazard determinations for each community listed below, in accordance with section 110 of the Flood Disaster Protection Act of 1973, 42 U.S.C. 4104, and 44 CFR 67.4(a). These proposed flood hazard determinations, together with the floodplain management criteria required by 44 CFR 60.3, are the minimum that are required. They should not be construed to mean that the community must change any existing ordinances that are more stringent in their floodplain management requirements. The community may at any time enact stricter requirements of its own or pursuant to policies established by other Federal, State, or regional entities. These flood hazard determinations are used to meet the floodplain management requirements of the NFIP. The communities affected by the flood hazard determinations are provided in the tables below. Any request for reconsideration of the revised flood hazard information shown on the Preliminary FIRM and FIS report that satisfies the data requirements outlined in 44 CFR 67.6(b) is considered an appeal. Comments unrelated to the flood hazard determinations also will be considered before the FIRM and FIS report become effective. Use of a Scientific Resolution Panel (SRP) is available to communities in support of the appeal resolution process. SRPs are independent panels of experts in hydrology, hydraulics, and other pertinent sciences established to review conflicting scientific and technical data and provide recommendations for resolution. Use of the SRP only may be exercised after FEMA and local communities have been engaged in a collaborative consultation process for at least 60 days without a mutually acceptable resolution of an appeal. Additional information regarding the SRP process can be found online at https://www.floodsrp.org/pdfs/ srp_overview.pdf. The watersheds and/or communities affected are listed in the tables below. The Preliminary FIRM, and where applicable, FIS report for each community are available for inspection at both the online location https:// hazards.fema.gov/femaportal/ SUPPLEMENTARY INFORMATION: AGENCY: SUMMARY: Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646–7659, or (email) patrick.sacbibit@fema.dhs.gov; or visit the FEMA Mapping and Insurance eXchange (FMIX) online at https:// www.floodmaps.fema.gov/fhm/fmx_ main.html. E:\FR\FM\29APN1.SGM 29APN1

Agencies

[Federal Register Volume 89, Number 83 (Monday, April 29, 2024)]
[Notices]
[Pages 33373-33374]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09047]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given that the 
Substance Abuse and Mental Health Services Administration's (SAMHSA) 
Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory 
Board (DTAB) will convene in open session in person and via web 
conference on June 4th, 2024, from 10:00 a.m. EST to 5:00 p.m. EST and 
in closed session on June 5th, 2024 from 9:00 a.m. EST to 12:00 p.m. 
EST.
    The board will meet in open-session June 4, 2024, from 10:00 a.m. 
EST to 5:00 p.m. EST to discuss the Mandatory Guidelines for Federal 
Workplace Drug Testing Programs, hear updates from the Nuclear 
Regulatory Commission, and discuss the availability of FDA 510(k) 
cleared assays and urine verses oral fluid prevalence data and specimen

[[Page 33374]]

validity and biomarker testing. Presentations include one by Faye 
Caldwell on industry moving parts pertaining to Oral Fluid 
implementation and another by Dr. Edward Cone regarding Johns Hopkins 
University study updates.
    The board will meet in closed session on June 5, 2024, from 9:00 
a.m. EST to 12:00 p.m. EST to discuss specimen validity testing data, 
challenges to Oral Fluid testing and the status of the Hair Mandatory 
Guidelines. All of these topics require input and discussion from Board 
Members as to the next steps of Federal Workplace Drug Testing. The 
DTAB meeting on June 5, 2024, from 9:00 a.m. EST to 12:00 p.m. EST, is 
closed to the public, as determined by the Assistant Secretary for 
Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 
552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).
    Meeting registration information can be completed at https://snacregister.samhsa.gov/. Web conference and call information will be 
sent after completing registration. Meeting information and a roster of 
DTAB members may be obtained by accessing the SAMHSA Advisory 
Committees website, https://www.samhsa.gov/about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis.
    Committee Name: Substance Abuse and Mental Health Services 
Administration Center for Substance Abuse Prevention Drug Testing 
Advisory Board.
    Dates/Time/Type: June 4, 2024, from 10:00 a.m. EST to 5:00 p.m. 
EST: OPEN; June 5, 2024, from 9:00 a.m. EST to 12:00 p.m. EST: CLOSED.
    Place: Substance Abuse and Mental Health Services Administration, 
5600 Fishers Lane, Rockville, MD 20857.
    To Submit Comments: Please send comments in writing at least 7 days 
prior to the meeting to the to the following email: 
[email protected].
    Contact: Lisa S. Davis, M.S, Social Science Analyst, Center for 
Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 
20857, Telephone: (240) 276-1440, Email: [email protected].

Anastasia Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2024-09047 Filed 4-26-24; 8:45 am]
BILLING CODE 4162-20-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.